Literature DB >> 9296223

Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center.

E T Janson1, L Holmberg, M Stridsberg, B Eriksson, E Theodorsson, E Wilander, K Oberg.   

Abstract

BACKGROUND: Little is known about factors related to prognosis in patients with carcinoid disease. In this study we have tried to identify such factors. PATIENTS AND METHODS: We have evaluated 301 consecutive carcinoid patients (256 midgut, 39 foregut and six hindgut) referred during 15 years for medical treatment with respect to tumor distribution, hormone production, prognostic factors and survival.
RESULTS: Survival was significantly shorter in midgut carcinoid patients with > or = 5 liver metastases or with high levels of urinary 5-hydroxyindoleacetic acid, plasma chromogranin A or neuropeptide K. By univariate analysis, these variables together with the presence of carcinoid syndrome were related to a higher risk of dying. In multivariate analyses, performed in the 71 patients with full information on all variables, advanced age and plasma chromogranin A > 5000 micrograms/l were independent predictors of overall survival.
CONCLUSIONS: Poor prognostic factors for midgut carcinoid patients were multiple liver metastases, presence of carcinoid syndrome and high levels of the tumor markers studied. In this study the only independent predictors of bad prognosis in midgut, carcinoid patients were advanced age, which however is inherently related to overall survival, and plasma chromogranin A > 5000 micrograms/l. Thus, chromogranin A may prove to be an important prognostic marker for patients with carcinoid tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9296223     DOI: 10.1023/a:1008215730767

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  104 in total

1.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

2.  Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer.

Authors:  Matthew Truong; Mackenzie R Cook; Scott N Pinchot; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2010-12-24       Impact factor: 5.344

3.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

4.  Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors.

Authors:  Thomas E Clancy; Tanya P Sengupta; Jessica Paulus; Fawzia Ahmed; Mei-Sheng Duh; Matthew H Kulke
Journal:  Dig Dis Sci       Date:  2006-06-07       Impact factor: 3.199

5.  Curative versus palliative surgical resection of liver metastases in patients with neuroendocrine tumors: a meta-analysis of observational studies.

Authors:  Stefano Bacchetti; Enrico Maria Pasqual; Serena Bertozzi; Ambrogio P Londero; Andrea Risaliti
Journal:  Gland Surg       Date:  2014-11

Review 6.  Advances in the treatment of neuroendocrine tumors.

Authors:  Matthew Kulke
Journal:  Curr Treat Options Oncol       Date:  2005-09

7.  Carcinoid and neuroendocrine tumors of the colon and rectum.

Authors:  T Philip Chung; Steven R Hunt
Journal:  Clin Colon Rectal Surg       Date:  2006-05

8.  AKT and PTEN expression in human gastrointestinal carcinoid tumors.

Authors:  Susan C Pitt; Ruth Davis; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Am J Transl Res       Date:  2009-02-28       Impact factor: 4.060

9.  Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.

Authors:  Marianne E Pavel; Alexandria T Phan; Edward M Wolin; Beloo Mirakhur; Nilani Liyanage; Susan Pitman Lowenthal; George A Fisher; Aaron I Vinik
Journal:  Oncologist       Date:  2018-10-24

10.  Effective treatment of pancreatic neuroendocrine tumours transfected with the sodium iodide symporter gene by 186Re-perrhenate in mice.

Authors:  Christoph G U Riese; Stephan Seitz; Meike L Schipper; Thomas M Behr
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-16       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.